Wellytics’ Post

According to the Global Cancer Statistics 2022 (GLOBOCAN), #ProstateCancer is the third most commonly diagnosed cancer in men worldwide. The risk of prostate cancer increases significantly with age, with the Centre for Disease Control and Prevention (CDC) reporting that 66% of cases occur in men over 65. Prostate cancer often leads to abnormal growth of the prostate, causing symptoms such as difficulty urinating, pain, and a weakened urinary stream. In this insightful article published by ABP Live, our #SubjectMatterExpert Dr.Shital munde, Consultant Histopathologist and Doctor In-Charge at the Global Reference Laboratory, Metropolis Healthcare, sheds light on prostate cancer, discussing its risk factors, early detection methods, treatment options, and more. Dr. Munde emphasizes the growing role of #ArtificialIntelligence in #Pathology, which is revolutionizing the field by enhancing diagnostic accuracy, standardizing cancer grading, and ultimately improving patient care. Advanced techniques like digital whole-slide imaging (WSI) have paved the way for AI to play a crucial role in prostate cancer diagnosis and grading, offering new hope in the fight against this prevalent disease. #Oncology #Histopathologist #ScientificExcellence #SpecialtyTesting #SuperSpeciality #ProstateCancer #AIInHealthcare #MetropolisLabs #EarlyDetection #PrecisionMedicine #ItsGoodToBeSure Dr. Nilesh Shah Dr Kirti Chadha Mohan Menon Kannan A Dr. Sanjay Gohil Dr Kavita Vijayakumar Dr Shaikhali Barodawala Vishal Wadhwa Dr.Shibani Ramchandran Adarsh Jeyasingh Balakrishnan Ashish Sahdev Vishal Vemul Supriya Nair https://lnkd.in/dRywhH4F

#ScientificWednesday Revolutionizing Brain Metastasis Prediction in Lung Cancer: A Game-Changer for Early Detection 🌟 🚨 Did you know that brain metastases (BMs) are the most common and deadliest brain tumors, particularly for patients with lung adenocarcinoma (LUAD)? Over 30% of LUAD patients develop BMs, which significantly shortens survival, with current methods detecting metastasis only after symptoms like headaches appear. 🔬 A groundbreaking study has now changed the game by developing a DNA methylation-based model that predicts the likelihood of brain metastasis up to 5 years in advance! This model uses methylation signatures from LUAD tumors to forecast BM development and even integrates clinical factors like cancer stage to provide personalized BM risk profiles for each patient. 💡 Key Breakthroughs: ▪️Predictive Power The model accurately predicts BM risk based on 5,553 differentially methylated CpG sites in LUAD tumors, allowing early intervention for high-risk patients. ▪️Non-invasive Liquid Biomarkers By analyzing circulating tumor DNA (ctDNA) from blood samples, the study developed plasma biomarkers that can detect BMs non-invasively. This means doctors can monitor BM development with a simple blood test, rather than relying solely on imaging or surgery. ▪️Immune Pathways and Metastasis The study also identified immune-related gene sets that are differentially methylated in LUAD tumors that develop BMs, providing insight into how immune dysfunction plays a role in metastasis. ▪️Clinical Utility The new nomogram outperforms current clinical methods like cancer staging in predicting BM risk, empowering healthcare providers to make more informed treatment decisions and consider early interventions such as radiotherapy or aggressive monitoring. 🔗 This innovative approach has the potential to transform clinical cancer care—enabling earlier BM detection, reducing neurological symptoms, and significantly improving survival rates in patients at risk. Read more: https://lnkd.in/dmB9tc4R #CancerResearch #BrainMetastasis #DNA #EarlyDetection #LungCancer #PrecisionMedicine #HealthcareInnovation #Biomarkers #LiquidBiopsy #MetastasisResearch Image source: https://lnkd.in/dZfgy-Rv

🚨Clinicians and scientists in Singapore have unveiled crucial insights into how gastric #cancer spreads to the peritoneum, thanks to a landmark study published in Gastroenterology. Led by Associate Professor Raghav Sundar MBBS, PhD, this breakthrough study could lead to more effective and targeted treatments for patients battling this aggressive form of cancer. 💡🔬 Additionally, the #PIANO trial led by Professor Jimmy Soh shows that combining Pressurised Intra-Peritoneal Aerosol Chemotherapy #PIPAC with immunotherapy could revolutionize treatment outcomes. 🌟 Read More: https://lnkd.in/gd-C8aHx #CancerResearch #NUSMedicine #GastricCancer #MedicalBreakthrough #InspiringInnovators #ClinicalTrials

Interesting insight on how the health of livers can impact tumor aggressiveness. Fatty livers have the potential to send signals (microRNAs) via extracellular vesicles that aid in cancer spread, and potentially diminish anti-tumor immune responses and the potency of immunotherapies. Could new treatments such as anti-miRNA oligonucleotides be useful as a control strategy? #microRNA #fattyliver #cancer Check out the article:

https://lnkd.in/eYkUn3EK #cancerresearch #oncology #cancertreatment Abstract Lymphatic transport maintains homeostatic health and is necessary for immune surveillance, and yet #lymphatic growth is often associated with solid tumour development and dissemination. Although tumour-associated lymphatic remodelling and growth were initially presumed to simply expand a passive route for regional #metastasis, emerging research puts lymphatic vessels and their active transport at the interface of metastasis, tumour-associated #inflammation and systemic #immune #surveillance. Here, we discuss active mechanisms through which lymphatic vessels shape their transport function to influence peripheral tissue immunity and the current understanding of how tumour-associated lymphatic vessels may both augment and disrupt antitumour immune surveillance. We end by looking forward to emerging areas of interest in the field of cancer immunotherapy in which lymphatic vessels and their transport function are likely key players: the formation of tertiary lymphoid structures, immune surveillance in the central nervous system, the microbiome, obesity and ageing. The lessons learnt support a working framework that defines the lymphatic system as a key determinant of both local and systemic inflammatory networks and thereby a crucial player in the response to cancer immunotherapy.

"The clinical significance of EMT is underscored by recent genomic studies to reconstruct the phylogenetic evolution of metastasis, showing how a significant proportion of metastases are seeded at a very early stage, before clinical manifestation of malignant diseases [15]. This is consistent with earlier experimental evidence showing that EMT can precede tumor formation or occur in very early pre-neoplastic lesions [16–18]. What remains to be seen is whether early disseminated tumor cells in human patients have undergone EMT and whether EMT-targeting therapy in early stage cancers can prevent later occurrence of metastasis." https://lnkd.in/dTZ5JSs2

What an incredible advancement in cancer research! 🌟 This research highlights a huge leap forward in predicting brain metastases from lung cancer—using DNA methylation to predict metastasis up to 5 years in advance. Early detection with non-invasive plasma biomarkers can completely change how we approach treatment, potentially saving lives by enabling timely interventions. Why should you check this out? Imagine being able to monitor metastasis with a simple blood test instead of waiting for symptoms to appear! This breakthrough offers hope for a more personalized and proactive cancer care approach. ✨ Questions to think about: How do you think non-invasive detection like this could impact long-term cancer survival rates? Could this method become a new standard in cancer care, and what challenges might we face in its implementation? What other areas of oncology might benefit from using similar DNA-based predictions? Join the conversation and let’s explore the future of early cancer detection together!

#innovation #cancerresearch #oncology #diagnosis #biomarkers https://lnkd.in/gaPnr9f6 Abstract Introduction Electronic nose (E-nose) technology has reported excellent sensitivity and specificity in the setting of #lung #cancer #screening. However, the performance of E-nose specifically for early-stage tumors remains unclear. Therefore, the aim of our study was to assess the diagnostic performance of E-nose technology in clinical stage I lung cancer. Methods This phase IIc trial (NCT04734145) included patients diagnosed with a single greater than or equal to 50% solid stage I nodule. Exhalates were prospectively collected from January 2020 to August 2023. Blinded bioengineers analyzed the exhalates, using E-nose technology to determine the probability of malignancy. Patients were stratified into three risk groups (low-risk, [<0.2]; moderate-risk, [≥0.2–0.7]; high-risk, [≥0.7]). The primary outcome was the diagnostic performance of E-nose versus histopathology (accuracy and F1 score). The secondary outcome was the clinical performance of the E-nose versus clinicoradiological prediction models. Results Based on the predefined cutoff (<0.20), E-nose agreed with histopathologic results in 86% of cases, achieving an F1 score of 92.5%, based on 86 true positives, two false negatives, and 12 false positives (n = 100). E-nose would refer fewer patients with malignant nodules to observation (low-risk: 2 versus 9 and 11, respectively; p = 0.028 and p = 0.011) than would the Swensen and Brock models and more patients with malignant nodules to treatment without biopsy (high-risk: 27 versus 19 and 6, respectively; p = 0.057 and p < 0.001). Conclusions In the setting of clinical stage I lung cancer, E-nose agrees well with histopathology. Accordingly, E-nose technology can be used in addition to imaging or as part of a “multiomics” platform.

The development of a new AI test to predict the risk of bowel cancer recurrence is a significant advancement in personalized medicine. By analyzing the number of immune cells in tumors, clinicians can make more informed decisions about chemotherapy treatment, potentially sparing patients unnecessary side effects. This innovative approach highlights the potential of AI in improving cancer care and outcomes. The CD3 Score test offers a reliable and efficient method for assessing the need for post-surgery chemotherapy, ultimately benefiting patients by guiding treatment decisions. The collaboration between researchers and industry partners underscores the importance of interdisciplinary efforts in advancing healthcare. #AI #cancerresearch #bowelcancer